INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
Subscribe
INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
SEARCH
SEARCH
advanced search
Pulmonary & Nasal Drug Delivery
184
Issue No 184 April 2026
April 10th, 2026
Download PDF
Issue 184 - Apr 2026
Inside the magazine
SUSTAINABILITY
Thomas Daly
Bespak
THE PHYSICS OF THE SWITCH: OPTIMISING pMDI DESIGN FOR LOW-CARBON LUNG DELIVERY
Thomas Daly and Tony Mallett discuss the transition to low-global warming potential propellants, examining the vital adjustments to the whole inhalation system necessary to support effective and safe dosing without hydrofluorocarbons.
NASAL
Dr Alan Watts
Catalent Pharma Solutions
EXPANDING HORIZONS IN LIQUID NASAL DRUG DEVELOPMENT
Dr Alan Watts and David Wilcox examine the current product designs in the nasal market landscape and outline key technical and regulatory considerations for liquid nasal drug products.
INDUSTRIALISATION
Stephen Gilmore
Crux Product Design
Interview: Inside The Crux Technology Centre
Stephen Gilmore discusses the opportunities and capabilities unlocked by Crux’s new Technology Centre located in Bristol, UK. Mr Gilmore provides an overview of the new capabilities provided by the facility and the potential it represents to the future of the company.
NASAL
Elsie Thomas
Nemera
DE-RISKING DEVICE SELECTION – WHY CHOOSE UNISPRAY FOR NALOXONE RESCUE APPLICATIONS
Elsie Thomas explains why UniSpray is a robust nasal platform for generic naloxone, based on an evidence-driven approach that combines usability studies, threshold analyses and interchangeability assessments, and how it ensures safe and reliable performance, intuitive use, and regulatory acceptability in real-world opioid overdose rescue situations.
PULMONARY
Simon Buchner
PARI
A NOVEL HUMAN FACTORS APPROACH FOR A NEW PLATFORM-BASED, BREATH-TRIGGERED NEBULISER
Simon Bucher, Dr Amy MacDonald and Dr John DeFoggi explain how human factors engineering is at the centre of the development of PARI’s breath-triggered eFlow
®
Integrated nebuliser, and consider how this approach preserves scientific rigour while avoiding redundant testing and ensuring efficient resource allocation.
NASAL
Eric Kaneps
LTS
REFRAMING THE ROLE OF NASAL SPRAYS IN AN INCREASINGLY PATIENT-CENTRIC DRUG DELIVERY LANDSCAPE
Eric Kaneps looks at the reality of nasal drug delivery for liquid formulations and considers how advances not only open new opportunities but can also be seen in the context of a groundswell of momentum around non-invasive, patient-centric delivery. Mr Kaneps reflects on how this shift in dynamics, coupled with a shift in mindset, is opening the door for pharmaceutical companies to expand their drug delivery options and fully optimise the development pathway for their molecule.
PULMONARY
Kasim Yilginc
GAPLAST
HOW SOFT MIST INHALERS WILL BREATHE NEW LIFE INTO DRUG DEVELOPMENT
Kasim Yilginc discusses the expanding importance and influence of the respiratory sector within pharmaceutical pipelines, including the role that soft mist inhalers are poised to play in improving patient outcomes and how GAPLAST’s AirlessMotion
®
bag-in-bottle technology can support the development of these inhalation devices.
PULMONARY
Dr Elijah Nazarzadeh
Nebu~Flow
ACOUSTIC WAVE PLATFORM NEBULISER FOR INHALED DELIVERY OF BIOLOGIC THERAPIES
Dr Elijah Nazarzadeh reports on the applications of Nebu~Flow, an acoustic wave-based nebuliser platform, addressing the challenges associated with drug delivery to the lungs via more efficient aerosolisation, enabling precise inhaled delivery of life-changing treatments.
PULMONARY
Paul Martin
Copley Scientific
AUTOMATING MDI ACTUATION: PRECISION DATA WITH LESS EFFORT
Paul Martin considers how automation can enhance testing for metered dose inhalers by removing the variability in actuation technique introduced by manual operation, presenting two case studies that demonstrate this potential improvement in data quality.
EXPERT VIEW
Dr Matthew Owen
INTRANASAL DRUG DELIVERY: FORMULATION, DEVICE DESIGN & CHARACTERISATION STRATEGIES
Dr Matthew Owen reviews the formulation and device challenges, designs and considerations that are shaping the nasal delivery market.
NASAL
SGD Pharma
MY STERINITY NASAL PLATFORM: A PRODUCT OF COLLABORATION
SGD Pharma discusses the advantages and benefits of the company’s recent partnership with Prince Sterilization Services, with a focus on the first product platform developed based on this collaboration – the My Sterinity Nasal platform of Type I glass primary containers for sensitive, long-term nasal therapeutics. Additionally, SGD Pharma highlights its presence at DCAT Week 2026.
Top
